176 related articles for article (PubMed ID: 32005797)
1. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
[TBL] [Abstract][Full Text] [Related]
2. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
3. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
[TBL] [Abstract][Full Text] [Related]
4. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
[TBL] [Abstract][Full Text] [Related]
5. BTK
Chen JG; Liu X; Munshi M; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Chan GG; Patterson CJ; Meid K; Gustine J; Dubeau T; Severns P; Castillo JJ; Hunter ZR; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
Blood; 2018 May; 131(18):2047-2059. PubMed ID: 29496671
[TBL] [Abstract][Full Text] [Related]
6. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
7. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
Liu X; Chen JG; Munshi M; Hunter ZR; Xu L; Kofides A; Tsakmaklis N; Demos MG; Guerrera ML; Chan GG; Jimenez C; Patterson CJ; Meid K; Keezer A; Castillo JJ; Treon SP; Yang G
Blood Adv; 2020 Jan; 4(1):141-153. PubMed ID: 31935288
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
[TBL] [Abstract][Full Text] [Related]
9. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
10. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
11. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
12. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
13. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
14. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
15. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
16. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
17. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
18. Genomic Alterations and MYD88
Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
20. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
